At the risk of stating the obvious, when evaluating a new EDC, step one is ensuring the EDC is in fact better. EDC technology ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, touches on how he would like to see greater industry ...

An article published by the Journal of the American Medical Association highlights recent updates made to the CONSORT ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...

Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...